The biopharmaceutical contract manufacturing market in North America is expected to grow from US$ 7,127.97 million in 2021 to US$ 12,847.38 million by 2028; it is estimated to register a CAGR of 8.8% from 2021 to 2028.
The contract manufacturing organization (CMO) offers many benefits to pharmaceutical companies, including reducing investments in facilities and drug development costs, thereby improving net cash flow. Outsourcing is cheaper and enhances the efficiency of manufacturing processes. It allows pharmaceutical & biotechnology companies to redirect resources to other areas. In the past few years, the contract manufacturing industry was a niche service market offering more manufacturing capacity or specific services to pharmaceutical companies. The rise of CMOs was fueled by the rising number of drug manufacturing failures. Pharmaceutical companies undertook many manufacturing facilities to develop innovative drugs in the past. However, the demand for manufacturing outsourcing has continuously risen to reduce the risk of overcapacities. Moreover, several pharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, further growing reliance on CMOS for manufacturing. Furthermore, the CMOs are vital in providing additional benefits to mitigate the risk of supply shortages by offering various sites for pharmaceutical companies with multisite supply strategies and backup capacities. For instance, in 2019, Samsung Biologics and GI Innovation signed a contract for immunochemotherapy. Under this agreement, Samsung Biologics provided services ranging from f-cell lines development to the production of phase-I drug substances. Therefore, the rising outsourcing of development, manufacturing, fill and finish, and packaging operations to contract manufacturing companies are expected to create significant market opportunities for market players, leading to the subsequent growth of the biopharmaceutical contract manufacturing market.
North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast to 2028 (US$ Million)
North America Biopharmaceutical Contract Manufacturing Market Segmentation
North America Biopharmaceutical Contract Manufacturing Market – By Product
-
Biologics
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Others
- Biosimilar
North America Biopharmaceutical Contract Manufacturing Market – By Service
-
Process Development
- Downstream Processing
- Upstream Processing
- Fill and Finish Operation
- Analytical and QC Studies
- Packaging
North America Biopharmaceutical Contract Manufacturing Market – By Source
- Mammalian
- Microbial-Based Biologics/ Non-Mammalian
North America Biopharmaceutical Contract Manufacturing Market– By Country
- The US
- Canada
- Mexico
North America Biopharmaceutical Contract Manufacturing Market-Companies Mentioned
- AbbVie Inc.
- Ajinomoto Co. Inc
- Boehringer Ingelheim International GmbH
- General Electric Company
- Lonza
- MERCK KGAA
- Samsung Biologics
- THERMO FISHER SCIENTIFIC INC
- WUXI BIOLOGICS
North America Biopharmaceutical Contract Manufacturing Market Strategic Insights
North America Biopharmaceutical Contract Manufacturing Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 7,127.97 Million |
| Market Size by 2028 | US$ 12,847.38 Million |
| CAGR (2021 - 2028) | 8.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
North America Biopharmaceutical Contract Manufacturing Market Country and Regional Insights
